Daiichi Sankyo Türkiye Establishes Oncology Business Unit

Daiichi Sankyo, which develops innovative healthcare solutions addressing medical needs to improve quality of life for people worldwide, continues to expand its operations in Turkey.

Drawing strength from its credible work in the cardiovascular disease field, the company has begun making its oncology portfolio available to patients in Turkey, introducing an innovative product that offers hope in breast cancer treatment to Turkish medicine.

Daiichi Sankyo, one of Japan's largest pharmaceutical companies that develops pioneering drugs and methods in its field drawing on over 120 years of scientific expertise, is committed to improving quality of life in more than 20 countries, including Turkey. In this context, Daiichi Sankyo Turkey, working to make a difference in the lives it touches every day, has established an oncology business unit and begun operations in the oncology field with its breast cancer product in cancer treatment.

Daiichi Sankyo Turkey develops healthcare solutions with the vision of becoming a global and innovative health organization that contributes to sustainable development of society, shaping its work by identifying long-term global needs. The company, which has long served as a reliable solution partner in the cardiology field in Turkey, has observed increased research and development activities centered on oncologic products worldwide, identified the need in this area, and made its oncology portfolio available to patients in Turkey, initially in breast cancer disease.

Continuing its activities with the goal of producing healthcare solutions that address unmet needs, Daiichi Sankyo Turkey Country Manager Nazlı Kayın, shared her happiness and pride at taking a new step in the field with innovative oncology products, saying "As Daiichi Sankyo, we believe that each patient journey is unique and much deeper than what is seen. We are continuing our work with determination as a team to respond in the best way to the needs of patients and their families during this challenging period. With our innovative antibody-drug conjugate (ADC) platform technology, we have developed an advanced treatment method for all tumor types and succeeded in overcoming seven fundamental limitations in ADC technology. We are very excited to introduce our new product to patients in Turkey with this positive development in cancer treatment".

Placing the human first at the center of everything it does with a focus on developing innovative treatment methods that address changing, transforming and differentiated medical needs, Daiichi Sankyo Turkey demonstrates its commitment to the oncology field with the goal of "making 8 innovative oncologic products available to patients in 7 years."